%0 Journal Article
%T 帕博利珠单抗在三阴性乳腺癌中的应用<br>The Application of Pembrolizumab in the Treatment of Triple Negative Breast Cancer
%A 陈波
%A 宋张骏
%J Advances in Clinical Medicine
%P 2360-2367
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/ACM.2024.142331
%X 乳腺癌是全球最常见的癌症，而三阴性乳腺癌(TNBC)是乳腺癌中恶性程度最高的亚型，标准的治疗手段仅限于手术、化疗和放疗，但是治疗效果并不理想。TNBC具有高度异质性以及较强的免疫原性，因此，免疫疗法以及靶向治疗被证明可以提高TNBC的总体生存率和反应，为TNBC提供了有前景的治疗选择。在这篇综述中，我们总结了在TNBC患者中基于免疫检查点抑制剂(ICIs)的各种治疗策略的研究进展，并探讨TNBC免疫治疗前景。<br />
Breast cancer is the most common cancer in the world, and triple-negative breast cancer is the most malignant subtype of breast cancer. The standard treatment methods are limited to surgery, chemotherapy and radiotherapy, but the treatment effect is not ideal. Triple-negative breast cancer has high heterogeneity and strong immunogenicity. Therefore, immunotherapy and targeted ther-apy have been proved to improve the overall survival rate and response of triple-negative breast cancer, providing a promising treatment option for triple-negative breast cancer. In this review, we summarized the research progress of various treatment strategies based on immune checkpoint inhibitors in triple-negative breast cancer patients, and discussed the prospect of triple-negative breast cancer immunotherapy.
%K 帕博利珠单抗，三阴性乳腺癌，免疫联合疗法，PD-1抑制剂<br>Pembrolizumab
%K Triple-Negative Breast Cancer
%K Immunotherapy Combination Therapy
%K PD-1 Inhibitor
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=80416